Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNC-035 in Relapsed or Refractory Non-Hodgkin's Lymphoma and Other Hematological Malignancies
NCT06066203Phase 2Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Nov 2023
- Primary completion
- Dec 2026
- Modality
- Prophylactic Vaccines, Multispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GNC-035 in non-Hodgkin lymphoma (NHL) and hematological malignancy, sponsored by Biokin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 21 days, Maximum Tolerated Dose at 21 days and 3 more. Started Nov 2023; status: recruiting.
02
Drugs
GNC-035
03
Conditions
non-Hodgkin lymphoma (NHL)hematological malignancy
Beyond the preview
Go deeper on NCT06066203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06066203.